Treatment of Pediatric Patients w/ Standard Risk Leukemia

Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)

November 22, 2017

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica; Francois, Laetitia Claire; Leffin, Melissa; Spinelli, Jennifer

    Trial Phone: 321.841.3837 ; 321.841.7561 ; 321.841.2008 ; 321.841.5357

  • IRB No: AALL0932

    Protocol Abbrev: AALL0932

    Principal Investigator: Vincent F. Giusti, MD

    Sub Investigators: AguilarBonilla, Ana MD; Eslin, Don MD; Martin, Rebecca, ARNP; Pope, Michele ARNP; Smith, Amy MD; Story, Allison ARNP; Sullivan, Kelly ARNP; Sutphin, Robert MD; Wieber, Laura ARNP; Levy, Alejandro MD

    Phase: Drug: Phase III

    Age Group: Pediatric

    Secondary Protocol No: AALL0932

    Treatment: Chemotherapy

    Applicable Disease Sites: Leukemia

    Therapies Involved: Drug therapy, Quality of Life Surveys, Biology Correlative Studies ID: NCT01190930

  • Objective

    A trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects

  • Key Eligibility

    Ages Eligible for Study: 1 Year to 30 Years; Genders Eligible for Study: Both;Accepts Healthy Volunteers: No